Just In
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.

Biotech

(7 search results)

The visionary biotech entrepreneur: Arun Asaithambi’s journey from PhD to NASDAQ
Innovation-led Indian healthcare market to hit $320 bn by FY28: Bain
Roche launches 2-in-1 biotech drug for breast cancer in India
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
The Ellas of Bharat Biotech: The gift of the jab
August records lowest M&A, PE deal values in 2018: Grant Thornton
Is Biocon undervalued?

Is Biocon undervalued?